A press release went out this week about the importation of medicinal cannabis product from Colombia and it is the usual Swiss cheese of holes containing vague assertions about the product and nothing about the conditions the product will apply to or what it might cost prospective patients.
We’re at a loss to understand what half of it even means
The first sentence sets the tone
Clever Leaves (the “Company”), a leading multi-national operator (MNO) and licensed producer of pharmaceutical-grade medical cannabinoids, today announced it has entered the Australian market with the arrival of its first white-labeled, semi-finished product shipment to Cannatrek
We would love to know what a semi-finished medical cannabis product is, as I’m sure would patients.
As to what the products were, not much detail was provided aside from being identified as various CBD oral solution concentrations distributed through Cannatrek’s physician and pharmacy networks across Australia.
These are apparently products not already available in Australia.
- Why are Clever Leaves unwilling to provide more detailed information about the product(s)?
- Who has tested these products?
- Where have they been tested? and
- What proof do patients have that these products are suitable for their particular condition and how do we know what they are ..?
Next.. “Clever Leaves’ entry into the emerging Australian medicinal cannabis market via Cannatrek’s distribution network shows not only its commitment to our marketplace, but its confidence in Cannatrek as its Australian distribution partner,” said Cannatrek CEO, Tommy Huppert.
Sorry guys but I presume you are paying the Colombians wholesale prices for a product that you will be retailing in Australia so what has confidence got to do with anything ?
“Commitment to our marketplace”. What does that even mean ?
And please can we stop with the “robust” word it really is getting long in the tooth
Here’s the full release there’s plenty more to be said about this guff but anybody with the vaguest understanding of the English language will know that a solid application of Grammerly and wordcount software is in the end what it is all about.
CLEVER LEAVES PRESS RELEASE
Clever Leaves Enters Australian Market with Supply Agreement with Cannatrek
Company to Supply White-Labeled, Semi-finished CBD Products for Commercial Purchase and Distribution Through Australian Physician and Pharmacy Networks.
Bogotá, August 11, 2020 – Clever Leaves (the “Company”), a leading multi-national operator (MNO) and licensed producer of pharmaceutical-grade medical cannabinoids, today announced it has entered the Australian market with the arrival of its first white-labeled, semi-finished product shipment to Cannatrek, an Australian seed-to-patient medicinal cannabis producer. The two-year supply agreement includes various CBD oral solution concentrations for distribution through physician and pharmacy networks in Australia. In accordance with all relevant import and export regulations, the initial product shipment was successfully received by Cannatrek last week and is commercially available for purchase.
The supply agreement offers products that are not currently available in Australia and strongly positions both parties in the rapidly growing Australian medical cannabis market. Under the terms of Australian medical cannabis regulation, all products in the agreement comply with Australian Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) requirements for manufacturing and testing.
“We are very pleased to expand our global footprint and distribute Clever Leaves EU GMP certified cannabis products through physician and pharmacy networks throughout Australia. We look forward to working closely with Cannatrek to increase patient access to medical cannabis solutions by leveraging their retail distribution network and trusted proprietary brands,” said Kyle Detwiler, CEO of Clever Leaves.
Cannatrek CEO, Tommy Huppert, commented, “Clever Leaves’ entry into the emerging Australian medicinal cannabis market via Cannatrek’s distribution network shows not only its commitment to our marketplace, but its confidence in Cannatrek as its Australian distribution partner. The global cannabis industry is maturing rapidly and we look forward to introducing quality products into Australia via our robust and growing network. We are extremely excited to have forged this relationship with Clever Leaves; it will support our mission to provide unique and affordable medicinal cannabis products to Australian patients to support their healthcare needs.”
Domestic demand for cannabis products Australia continues to rapidly increase. According to New Frontier Data, by December 2020, the market will support a projected 25,000–30,000 active patients, and based on the current rate of growth, Australian health regulators expect the number of medical cannabis prescriptions to reach at least 70,000.
Clever Leaves continues to partner with businesses around the world to offer EU GMP certified products through its vertically-integrated business platform and supply chain process expertise. For all business inquiries, please visit Clever Leaves’ direct to business sales platform, www.cleverleaves360.com, to set an appointment with a Clever Leaves’ business consultant.
To exhaust ourselves a little further we thought we’d better take a quick look at Clever Leaves
Here’s some info from their site….They say the are operating in a number of jurisdictions according to the map below published on their website
Here’s their leadership team information below .
Nothing that really surprises and reads like a bog standard US big end of town cannabis leadership team. Eg a finance/ Wall St type person (Blackstone), somebody with experience in the “security” industry(Chubb), a govt insider (Director of Drug Policy for the Colombian Ministry of Justice and Law) and somebody with experience at a agricultural / F&B company with monopolistic tendencies (Chiquita-Fresh Express) All CV’s that will appeal to a certain type of investor
Essentially it is the ever onward march of vertical integration to try and control a market, in their case Colombia.
Here are their brands.
We suggest it is this first section below that Australian patients should look at and ask the following questions before
- What are these products and what conditions do they apply to?
- Are they supplied to Cannatrek white label and then branded in Australia?
- Where are these products being tested Colombia? Australia? USA?
- What are they being tested for ?
- It’s probably worth asking Cannatrek what they are paying to compare what you might be paying as a patient?
- What’s the shelf life of the products?